Experimental Screening Study of the Antiarhythmic Activity of Empagliflosin
https://doi.org/10.33647/2074-5982-16-3-73-76
Abstract
The antiarrhythmic activity of the type 2 sodium glucose co-transporter inhibitor Empagliflozin was studied in a model induced by calcium chloride in C57BL mice. It was found that preliminary administration of Empagliflozin at a dose of 1 mg/kg prevented CaCl2-induced ventricular arrhythmia and death during four periods of the biological half-life of the drug.
About the Authors
M. V. Krasnova
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Marina V. Krasnova
197376, Saint Petersburg, Professora Popova str., 14
S. V. Okovitiy
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Sergey V. Okovitiy, Dr. Sci. (Med.), Prof.
197376, Saint Petersburg, Professora Popova str., 14
A. N. Kulikov
Pavlov First Saint Petersburg State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Alexander N. Kulikov, Dr. Sci. (Med.), Prof.
197022, Saint Petersburg, L’va Tolstogo str., 6–8
D. Yu. Ivkin
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Dmitry Yu. Ivkin, Cand. Sci. (Biol.), Assoc. Prof.
197376, Saint Petersburg, Professora Popova str., 14
E. Kaschina
Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité – Universitätsmedizin Berlin
Germany
Germany
Elena Kaschina, Dr. Sci. (Med.)
10117, Berlin, Charitépl., 1
References
1. Kubota Y., Yamamoto T., Tara S., et al. Effect of Empagliflozin versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale. Diabetes Ther. 2018;9(5):2107:2116.
2. Mustroph J., Wagemann O., Lücht C.M., et al. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642;648. DOI: 10.1002/ehf2.12336.
3. Rajasekeran H., Lytvyn Y., Cherney D.Z. Sodiumglucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney International. 2016;89(3):524–526.
4. Scheen A.J. Reduction in cardiovascular and allcause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes & Metabolism. 2016;42(2):71–76.
5. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373(22):2117–2128.
Review
For citations:
Krasnova M.V., Okovitiy S.V., Kulikov A.N., Ivkin D.Yu., Kaschina E. Experimental Screening Study of the Antiarhythmic Activity of Empagliflosin. Journal Biomed. 2020;16(3):73-76. (In Russ.) https://doi.org/10.33647/2074-5982-16-3-73-76
Views:
451
Email this article 
